Tags: Drug.

Milatuzumab is a monoclonal antibody for the treatment of multiple myeloma and other hematological malignancies.This drug was developed by Immunomedics Inc.It has been linked to doxorubicin to form an antibody-drug conjugate for treatment of relapsed multiple myeloma. A phase I/II clinical trial has started.

ATC prefix
none
CAS number
899796-83-9
FDA UNII code
2OP4E0GC6V

Loading...

This page contains content from the copyrighted Wikipedia article "Milatuzumab"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.